Endometrial Adenocarcinoma
Showing NaN - NaN of 5
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States
Active, not recruiting
- Endometrial Adenocarcinoma
- +9 more
- Bevacizumab
- +5 more
-
Phoenix, Arizona
- +232 more
Jan 12, 2023
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma Trial in United States
Completed
- Endometrial Adenocarcinoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Hartford, Connecticut
- +21 more
Oct 13, 2020
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States
Completed
- Endometrial Adenocarcinoma
- +3 more
- Diagnostic Laboratory Biomarker Analysis
- Selumetinib
-
Los Angeles, California
- +71 more
Jul 19, 2019
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma Trial in United States
Completed
- Endometrial Adenocarcinoma
- +8 more
-
Burbank, California
- +58 more
Sep 8, 2017
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma Trial in United States (Paclitaxel,
Completed
- Chemotherapeutic Agent Toxicity
- +14 more
-
Chicago, Illinois
- +6 more
Dec 29, 2014